| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 12th February 2021 | Ron Bentsur | 23,419 | Exercise of derivative | $4.25 | $99,530.75 |
| 12th February 2021 | Ron Bentsur | 23,419 | Open or private sale | $6.36 | $148,944.84 |
| 11th February 2021 | Ron Bentsur | 1,500 | Open or private sale | $6.28 | $9,420.00 |
| 25th August 2020 | Ron Bentsur | 1,580 | Open or private sale | $5.95 | $9,406.21 |
| 24th August 2020 | Ron Bentsur | 3,889 | Open or private sale | $5.68 | $22,104.30 |
| 21st August 2020 | Ron Bentsur | 3,246 | Open or private sale | $6.05 | $19,650.63 |
| 20th August 2020 | Ron Bentsur | 3,778 | Open or private sale | $6.29 | $23,779.87 |
| 19th August 2020 | Ron Bentsur | 6,533 | Open or private sale | $6.32 | $41,265.69 |
| 18th August 2020 | Ron Bentsur | 4,578 | Open or private sale | $5.83 | $26,691.11 |
| 17th August 2020 | Ron Bentsur | 4,413 | Open or private sale | $5.72 | $25,226.03 |
Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
Ticker: STML
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1264587
Employees: 100
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
